GRAIL Inc

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GRAIL Inc reports revenue growth and narrows sales guidance

GRAIL Inc's Q3 2024 performance reflects positive revenue growth and demand for its Galleri tests, despite ongoing losses.
The company's financial position remains stable with a substantial cash balance, supporting future strategic initiatives and investments.
While challenges persist in achieving profitability, narrowing sales growth guidance and improved cost management signal progress towards long-term sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Completes Enrollment of More Than 35,000 Participants in the PATHFINDER 2 Study;  Results From the First 25,000 Participants Expected in the Second Half of 2025 GRAIL Completes Final Study Visits for the NHS-Galleri Trial; Final Results Expected in 2026 MENLO PARK, Calif. , July 15, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today provided an update on the PATHFINDER 2 and NHS-Galleri registrational clinical trials evaluating the Galleri® multi-cancer early detection (MCED) test.

GRAIL Advances the Galleri® Registrational Clinical Trial Program

TELUS

The 'Undercovered' Dozen highlights twelve ideas from the previous week on stocks with limited coverage. If you're looking for yield, two preferred stock ideas are featured, as well as other high yielding dividend-focused options. A spin-off situation, a zinc-based energy storage solutions provider, and Europe's leading semiconductor foundry are also in focus this week.

Undercovered Dozen: Telus Corporation, X-FAB Silicon Foundries, GRAIL, And More

Illumina

Illumina has finally completed the divestiture of GRAIL, ending a disastrous chapter in its history. The Company paid $8bn to acquire the cancer testing business it helped to create, which proved to be a disastrous mistake, triggering three years of share price losses. Newly spun-out GRAIL faces challenges in the competitive cancer testing market, while Illumina returns to its profitable gene sequencing business.

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to the recently spun-off Grail Inc.

Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2

On June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitalization: $3.26 billion). On June 25, 2024, both the stocks started regular way trading with, new Illumina opening at $108.24, making an intraday high of $112.49, low of $106.26 and closed at $109.84.

Illumina Completes Spin-Off Of GRAIL

GRAIL shares started trading on Nasdaq after a spin-off from Illumina, as the EU's regulatory scrutiny weighed on the prior merger. The company offers the Galleri blood test for early cancer detection, with major sales potential still behind MCED legislation, FDA approval, and medical plan reimbursement implementation. The industry has fierce competition among MCED tests between companies, adding significantly to GRAIL's competitive risks.

GRAIL: Ambitious Illumina Spin-Off Trading At Intriguing Valuation

The world of biotech stocks got a new member today. Grail (NASDAQ: GRAL ) has successfully completed its spinoff from industry leader Illumina (NASDAQ: ILMN ).

GRAL Stock Alert: 7 Things to Know as Grail Starts Trading Today

Shares of Grail fell as much as 11.7% in their market debut on Tuesday after being spun out of gene-sequencing company Illumina.

Grail's shares fall in Nasdaq debut after spin-off from Illumina

U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina , is betting that commercial partnerships with health systems, employers and life insurance companies of its flagship cancer-detection test will power its near-term growth as an independent company.

Grail bets big on flagship cancer test after spin-off from Illumina

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC) will be listed and commence regular-way trading on the Nasdaq as of tomorrow, June 25, 2024.

GRAIL to Begin Trading on the Nasdaq Stock Exchange

News for GRAIL Inc Stock (GRAL)